Asceneuron is based in Lausanne, Vaud, CH. It has raised $100M in total funding. Latest round: Series C.
Asceneuron funding overview
Asceneuron is based in Lausanne, Vaud, CH. Asceneuron has raised $100M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series C announced in July 2024. The round record for Asceneuron runs through 2024; nothing later has been disclosed. Investors on record include Novo Holdings, EQT Group Life Sciences, OrbiMed, SR One, M Ventures, Sofinnova Partners and 2 others. 8 distinct backers are named across the disclosed rounds.
Asceneuron at a glance
Total raised
$100M
Latest round
Series C
Latest round date
July 2024
Headquarters
Lausanne, Vaud, CH
Notable investors
Novo Holdings, EQT Group Life Sciences, OrbiMed, SR One, M Ventures, Sofinnova Partners, GSK Equities Investment Limited, Johnson & Johnson Innovation JJDC Inc.
Frequently asked about Asceneuron funding
How much has Asceneuron raised?
Asceneuron has raised $100M in total disclosed funding across the rounds on record.
Who has invested in Asceneuron?
Novo Holdings, EQT Group Life Sciences, OrbiMed, SR One, M Ventures, Sofinnova Partners are named among the investors backing Asceneuron.
What was the latest Asceneuron funding round?
The most recent disclosed round is a Series C, announced in July 2024.
Where is Asceneuron based?
Asceneuron is based in Lausanne, Vaud, CH.
When did Asceneuron last raise?
The last disclosed Asceneuron round closed in July 2024 at Series C.
Round data for Asceneuron is compiled from public filings and announcements; blank fields mean nothing has been disclosed rather than nothing exists. Continue with the companies in Lausanne and backer lists below.
